100% cure rate for new colorectal cancer treatment


"Researchers at Memorial Sloan Kettering Cancer Center in New York City and Massachusetts Institute of Technology in Boston have developed a new, three-step system that uses nuclear medicine to target and eliminate colorectal cancer. In this study with a mouse model, researchers achieved a 100-percent cure rate -- without any treatment-related toxic effects. The study is reported in the November featured article in The Journal of Nuclear Medicine.

Until now, radioimmunotherapy (targeted therapy) of solid tumors using antibody-targeted radionuclides has had limited therapeutic success. "This research is novel because of the benchmarks reached by the treatment regimen, in terms of curative tumor doses, with non-toxic secondary radiation to the body's normal tissues," explains Steven M. Larson, MD, and Sarah Cheal, PhD, of Memorial Sloan Kettering Cancer Center. "The success in murine tumor models comes from the unique quality of the reagents developed by our group, and the reduction to practice methodology, including a theranostic approach that can be readily transferred, we believe, to patients."

Theranostics, a term derived from therapy and diagnostics, is the use of a single agent to both diagnose and treat disease. The theranostic agent first finds the cancer cells, then destroys them, leaving healthy cells unharmed -- minimizing side effects and improving quality of life for patients.

In this study, the glycoprotein A33 (GPA33), an antigen found on over 95 percent of primary and metastatic human colorectal cancers, was targeted with a bispecific antibody for A33 tumor antigen and a second antibody for a small-molecule radioactive hapten, a complex of lutetium-177 (177Lu) and S-2-(4-aminobenzyl)1,4,7,10-tetraazacyclododecane tetra-acetic acid (177Lu-DOTA-Bn).

The DOTA-pretargeted radioimmunotherapy (PRIT) strategy was tested on a mouse model. In randomly selected mice undergoing treatment, serial SPECT/CT imaging was used to monitor treatment response and calculate radiation-absorbed doses to tumors. All the DOTA-PRIT-treated animals tolerated the treatment well, and all 9 assessed mice had no trace of cancer remaining upon microscopic examination. There was also no detectable radiation damage to critical organs, including bone marrow and kidneys.

The 100-percent cure rate in the mouse model is a promising preliminary finding that suggests that anti-GPA33-DOTA-PRIT will be a potent radioimmunotherapy regimen for GPA33-positive colorectal cancer tumors in humans."
They could be reluctant to say that for humans very soon, yet for mouse with short lifespans, they can better wait for other natural causes to kill the mice.

Possibly Related Threads…
Thread Author Replies Views Last Post
  New cure for baldness discovered in Great Britain Magical Realist 0 362 May 10, 2018 05:49 PM
Last Post: Magical Realist
  FDA approves use of MDMA for treatment of PTSD Magical Realist 4 882 Dec 15, 2017 01:34 PM
Last Post: RainbowUnicorn
  Marijuana use: Stroke, heart failure risk + Future resveratrol treatment of diabetes C C 2 619 Mar 15, 2017 07:21 PM
Last Post: RainbowUnicorn
  New Alzheimer's treatment reverses memory loss Magical Realist 6 1,064 Feb 16, 2017 04:20 PM
Last Post: Ben the Donkey
  Malaria, cure for cancer? elte 1 514 Oct 15, 2015 05:47 AM
Last Post: C C
  Cure for macular degeneration looks promising Magical Realist 0 426 Sep 30, 2015 07:23 PM
Last Post: Magical Realist
  A cure for asthma Magical Realist 0 620 Apr 24, 2015 06:44 PM
Last Post: Magical Realist
  Stem cells cure baldness Magical Realist 0 590 Jan 28, 2015 05:41 PM
Last Post: Magical Realist

Users browsing this thread: 1 Guest(s)